Connect Biopharma Holdings Limited (CNTB)

Market Cap	159.39M
Revenue (ttm)	64,000 -99.8%
Net Income	-55.48M
EPS	-1.00
Shares Out	56.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	162,294
Open	3.000
Previous Close	2.990
Day's Range	2.750 - 3.070
52-Week Range	1.230 - 3.820
Beta	-0.18
Analysts	Strong Buy
Price Target	8.67 (+207.45%)
Earnings Date	May 14, 2026

About CNTB

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company’s lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 19, 2021
• Employees: 62
• Stock Exchange: NASDAQ
• Ticker Symbol: CNTB
• Website: https://www.connectbiopharm.com

Financial Performance

In 2025, CNTB's revenue was $64,000, a decrease of -99.75% compared to the previous year's $26.03 million. Losses were -$55.48 million, 255.0% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for CNTB stock is "Strong Buy." The 12-month stock price target is $8.67, which is an increase of 207.45% from the latest price.

Price Target

$8.67

(207.45% upside)

Analyst Consensus: Strong Buy